Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms EMPACTA
- Sponsors Genentech
- 08 Feb 2023 Status changed from active, no longer recruiting to completed.
- 21 Dec 2022 According to a Genentech Pharmaceuticals media release, company announced that the U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), based on the results from the RECOVERY trial, as well as the EMPACTA trial.
- 04 Apr 2022 According to a Genentech media release, a decision on U.S. FDA approval is expected in the second half of this year.